Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00107614
Status:
TERMINATED
Last Update Posted:
2011-08-26
First Post:
2005-04-05
Brief Title:
DT PACE Tandem Autologous Transplant Maintenance Therapy for Waldenstroms Macroglobulinemia Patients
Sponsor:
University of Arkansas
Organization:
University of Arkansas
Study Overview
Official Title:
UARK 2002-10 A Phase II Study of DT PACE Induction Followed by Tandem Autologous Transplant and Maintenance Therapy for Patients With Advanced andor Symptomatic Waldenstroms Macroglobulinemia
Status:
TERMINATED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Terminated due to poor accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out what the response is and the side effects are with chemotherapy using a combination of drugs called DT PACE Dexamethasone Thalidomide cis-Platinum Adriamycin Cyclophosphamide and Etoposide Rituxan followed by two autologous transplants
Detailed Description:
Approximately 25 patients male or female age 18 and older regardless of race or ethnicity will participate in this study at UAMS University of Arkansas for Medical Sciences only
Participants will receive two courses of chemotherapy with a regimen called DT PACE Rituxan This regimen consists of 6 drugs Dexamethasone Thalidomide cis-Platinum Adriamycin Cyclophosphamide and Etoposide
Participants will receive two courses of chemotherapy with a regimen called DT PACE Rituxan This regimen consists of 6 drugs Dexamethasone Thalidomide cis-Platinum Adriamycin Cyclophosphamide and Etoposide
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None